Pooled analysis

ReCor Medical Announces Consistent Reduction of Blood Pressure in Pooled Analysis of Three Clinical Trials at AHA 2022

Retrieved on: 
Sunday, November 6, 2022
Health, Clinical Trials, Cardiology, Medical Devices, American Heart Association, Blood pressure, Surgeon, Sex, TRIO, Hypertension, Physician, Columbia University, Columbia University Irving Medical Center, Data, BP, Columbia University Vagelos College of Physicians and Surgeons, Patient, Pooled analysis, Pharmaceutical industry, Medicine

ReCor Medical, Inc. (ReCor) and its parent company, Otsuka Medical Devices Co., Ltd. today announced consistent and significant blood pressure (BP) lowering results across a range of patients with uncontrolled hypertension, including across differences in age, sex, baseline blood pressure, medication level and ethnicity.

Key Points: 
  • ReCor Medical, Inc. (ReCor) and its parent company, Otsuka Medical Devices Co., Ltd. today announced consistent and significant blood pressure (BP) lowering results across a range of patients with uncontrolled hypertension, including across differences in age, sex, baseline blood pressure, medication level and ethnicity.
  • Pooling the data from the RADIANCE program demonstrates that treatment with the Paradise uRDN System results in a consistent reduction in blood pressure across differing severities of hypertension.
  • It is very important that the RADIANCE pooled analysis demonstrated a consistent blood pressure reduction in patients across a range of hypertension and both with and without antihypertensive medication, thus broadening the potential applicability of uRDN.
  • The RADIANCE studies are double-blind, randomized, sham-controlled trials designed to provide information about the ability of the Paradise uRDN System to treat high blood pressure.

Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project

Retrieved on: 
Sunday, June 5, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Biomarker, Prognosis, IDC, Vanderbilt University Medical Center, Genome, Behavior, Survival, Bone, Breast, SEER, Neoplasm, Cancer, Mining, Pooled analysis, TNBC, IMPACT, High Risk, Program, IHC, MAF, Diagnosis, Collection, MPH, Triple-negative breast cancer, Biology, Physician, Blueprint, Patient, Gene expression, Oncology, FLEX, Oncotype (Denmark), Department, Woman, Science, Gene amplification, Facebook, Research, Society, Classification, LinkedIn, Marie Cassidy, Breast cancer, Department of Medicine – University of Pamplona, ASCO, Gene, Risk, Twitter, Surgeon, White, Recurrence, Medical imaging, Dietary supplement, Pharmaceutical industry, Black, MD, Epidemiology, MammaPrint

In addition, Agendia will present several sub-studies highlighting the FLEX Trials approach to cancer research by accelerating impactful data generation, aimed at redefining cancer care.

Key Points: 
  • In addition, Agendia will present several sub-studies highlighting the FLEX Trials approach to cancer research by accelerating impactful data generation, aimed at redefining cancer care.
  • FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data [Ma, C., et al.]
  • shares data from the 38 investigator-initiated sub-studies including five investigating racial disparities approved within the FLEX Real World Evidence Trial ( NCT03053193 ).
  • Agendias commitment to expanding our understanding of breast cancer to improve outcomes for women with breast cancer is astounding, exemplified by the FLEX Real World Evidence Trial.

 New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier

Retrieved on: 
Thursday, May 26, 2022
Health, Genetics, Science, Other Science, Oncology, Cancer, Physician, Pooled analysis, Risk, Annual general meeting, Incidence, Patient, Prostate, Health, SEER, Association, Watchful waiting, Society, Investor, Form 10-Q, American Society of Clinical Oncology, Urology, Metastasis, NanoString Technologies, RP, Prostate cancer, Man, Forward-looking statement, ASCO, National Cancer Research Institute, Twitter, SEC, Database, Diagnosis, Laboratory, Annual report, Medical imaging, Security (finance), Epidemiology

Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, population-based study reinforce the clinical utility of the DecipherProstate genomic classifier.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, population-based study reinforce the clinical utility of the DecipherProstate genomic classifier.
  • The findings, which will be shared for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, suggest that the Decipher Prostate tests are helping to guide prostate cancer treatment decisions and improve patient care.
  • The resulting data are exciting, because they demonstrate that population-based prostate cancer treatment patterns are independently associated with Decipher classifier scores.
  • Decipher Prostate is a 22-gene, microarray-based genomic test intended to help inform treatment decisions for men with localized prostate cancer at initial diagnosis (Decipher Prostate Biopsy) and after surgical removal of the prostate (Decipher Prostate RP).

Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases

Retrieved on: 
Thursday, February 3, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Diagnosis, Data, Risk, Patient, Registry, SEER, List of life sciences, International Institute for Population Sciences, Sentinel lymph node, Uveal melanoma, National, National Cancer Institute, SEC, Program, Poster, SRP, Twitter, CM, Securities Act of 1933, Research, COVID-19, Skin cancer, Population, Cancer, Instagram, Surveillance, Recurrence, Epidemiology, Pooled analysis, Skin, Gene, Company, NCI, Personal Data Privacy and Security Act of 2009, Time, Survival, Securities Exchange Act of 1934, Disease management, DecisionDx-UM, Data collection, Data analysis, SLN, LinkedIn, Conference, Nasdaq, Atopic dermatitis, Vaccine, Mobile phone, Medical device, Medical imaging, Pharmaceutical industry, Facebook, DecisionDx-Melanoma, the SEER Program, Castle Biosciences, DECISIONDX-MELANOMA, THE SEER PROGRAM, CASTLE BIOSCIENCES

The Company expects to continue collaborating with the NCI to link the SEER registries CM cases diagnosed post-2018 with DecisionDx-Melanoma test results.

Key Points: 
  • The Company expects to continue collaborating with the NCI to link the SEER registries CM cases diagnosed post-2018 with DecisionDx-Melanoma test results.
  • We are excited to collaborate with the NCI to link DecisionDx-Melanoma test results with the SEER registries data, said Derek Maetzold, president and chief executive officer of Castle Biosciences.
  • The SEER registries linked CM cases in the registry to DecisionDx-Melanoma testing data provided by Castle Biosciences.
  • The SEER Program registries collect data on cancer cases diagnosed in their catchment area from various locations and sources throughout the United States.

Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients

Retrieved on: 
Monday, October 25, 2021
Safety, Program, Neoplasm, Twitter, U.S. Securities and Exchange Commission, Dalhousie University, Radiation, Survival rate, RWE, NCI, North American Association of Central Cancer Registries, Cyberknife, Erasmus, Incidence, Association, Survival, BEIR, Security (finance), Private Securities Litigation Reform Act, Intelligence, SLC Agrícola, Literature, Pooled analysis, Risk, Panacea Medical Technologies, Real, Synchrony, International Institute for Population Sciences, SLC, Breast cancer, SEC, ABPI, FABS, Surveillance, Erasmus MC, SRP, Population, Frontiers, Technology, LinkedIn, Annual report, Lung, Database, Patient, NASDAQ, YouTube, SEER, Time, Forward-looking statement, Mortality, Medical imaging, Pharmaceutical industry

SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.

Key Points: 
  • SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.
  • The addition of radiotherapy can extend survival that may be offset by the development of a secondary cancer like lung tumors many years following treatment.
  • This study reinforces the unparalleled accuracy of a 4-like robotic CyberKnife platform and shows its tremendous potential as a treatment for early-stage breast cancer," said Suzanne Winter, president at Accuray.
  • Breast cancer stage distribution and number of new cases were obtained from the North American Association of Central Cancer Registries (NAACCR).

Allergan To Present Data From 13 Abstracts At The 2018 American Society For Dermatologic Surgery Meeting In Phoenix

Retrieved on: 
Thursday, October 11, 2018
Allergan, Pooled analysis

DUBLIN, Oct. 11, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October 11-14.

Key Points: 
  • DUBLIN, Oct. 11, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October 11-14.
  • ATX-101 Treatment Among Adults with Mild Submental Fat: Data from CONTOUR.
  • Preplatysmal Fat Volume is Reduced by Approximately 25% Among ATX-101 Treatment Responders: Analysis of the REFINE Data.
  • Efficacy, Safety, and Patient-Reported Outcomes Following OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Pooled Analysis of Two Phase 3 Pivotal Trials.